semaglutide nash phase 3 Trial of in Metabolic Dysfunction–Associated Steatohepatitis The weight-loss-independent hepatoprotective benefits of – Semaglutide 2·4 mg once weekly

Our study recruited participants with a suboptimal clinical response, encompassing a suboptimal initial weight loss response and weight regain after an initial period of weight loss

Common benefits include reduced daily hunger, quicker satiety, diminished high-calorie cravings, and enhanced energy to incorporate physical activityall vital for sustaining healthy weight loss

Endocrinol Metab (Seoul) 2019;34(3):247262

The decision to switch is personalized, considering individual health profiles, weight loss goals, lifestyle, and cost-effectiveness, ensuring the most suitable and affordable approach for each patient